BioMarin Pharmaceutical Inc.

NasdaqGS:BMRN Lagerbericht

Marktkapitalisierung: US$13.4b

BioMarin Pharmaceutical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

BioMarin Pharmaceutical hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag1.9%
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Gewinn pro AktieUS$1.35
Prognose der Dividendenrendite0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly

Sep 21
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

Aug 21

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

Jul 24

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Jun 01
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Apr 21
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Mar 30
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Jan 19

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Jan 05
Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Dec 15
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Nov 03
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Aug 09
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Jul 18
We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 09
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Apr 18
Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27
These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25
Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

BioMarin: A Good Anchor For Your Biotech Portfolio

May 10

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von BMRN in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von BMRN gestiegen sind.

Dividendenrendite im Vergleich zum Markt

BioMarin Pharmaceutical Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von BMRN im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (BMRN)n/a
Untere 25 % des Marktes (US)1.4%
Markt Top 25 % (US)4.3%
Branchendurchschnitt (Biotechs)1.9%
Analystenprognose (BMRN) (bis zu 3 Jahre)0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von BMRN im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von BMRN im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von BMRN, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da BMRN keine Ausschüttungen gemeldet hat.

Entdecken Sie dividendenstarke Unternehmen

7D

1Y

7D

1Y

7D

1Y